Biocept (FRA:B00) Institutional Ownership : 0.47% (As of Jun. 07, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Biocept Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biocept's institutional ownership is 0.47%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biocept's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biocept's Float Percentage Of Total Shares Outstanding is 99.85%.

Biocept Institutional Ownership Historical Data

The historical data trend for Biocept's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept Institutional Ownership Chart

Biocept Historical Data

The historical data trend for Biocept can be seen below:

	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31
Institutional Ownership	10.02	10.02	1.62	1.63	0.66	0.26	0.26	0.24	0.47	0.47

Biocept Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Biocept (FRA:B00) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (FRA:B00) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BIOCQ:USA

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Biocept (FRA:B00) Headlines

No Headlines